论文部分内容阅读
目的探讨多西紫杉醇联合强的松治疗激素难治性前列腺癌的临床疗效。方法 64例激素难治性前列腺癌患者随机分为治疗组(32例)和对照组(32例)。两组均每3周(1个治疗周期)用多西紫杉醇75mg/m2静脉滴注1h。治疗组加用强的松5mg,每天2次。比较疗效及不良反应。结果 64例中,5例完成了8个周期治疗,15例6个周期,42例4个周期,2例1个周期。治疗组化疗后总有效率为87.5%,明显高于对照组的56.2%(P<0.05)。治疗组疼痛减轻效果也优于对照组。两组不良反应相仿(P>0.05)。结论多西紫杉醇联合强的松治疗激素难治性前列腺癌疗效确切,明显改善患者生活质量。
Objective To investigate the clinical efficacy of docetaxel combined with prednisone in the treatment of hormone refractory prostate cancer. Methods Sixty-four patients with hormone-refractory prostate cancer were randomly divided into treatment group (32 cases) and control group (32 cases). Both groups were given intravenous infusion of docetaxel 75 mg / m2 for 1 h every 3 weeks (1 cycle of treatment). Treatment group plus prednisone 5mg, 2 times a day. Comparison of efficacy and adverse reactions. Results Among 64 cases, 5 completed 8 cycles of treatment, 15 cases of 6 cycles, 42 cases of 4 cycles and 2 cases of 1 cycle. The total effective rate of the treatment group was 87.5% after chemotherapy, which was significantly higher than that of the control group (56.2%, P <0.05). The pain relief in the treatment group was also better than that in the control group. Adverse reactions in both groups were similar (P> 0.05). Conclusion Docetaxel combined with prednisone treatment of hormone refractory prostate cancer is effective and significantly improve the quality of life of patients.